Market Place
Sourcing Support
Onvansertib Shows Positive Ph 2 Result in RAS-Mutated mCRC Cancer
02 Jun 2026 //
GLOBENEWSWIRE
Delhi HC Allows Intas To Sell Bevatas Drug, Overturns Sun Pharma
02 Jun 2026 //
ECONOMICTIMES
Outlook Announces Resubmission of BLA to FDA for ONS-5010
01 Jun 2026 //
GLOBENEWSWIRE
Pfizer`s Braftovi Regimen Nearly Doubles PFS in mCRC
31 May 2026 //
PRESS RELEASE
Outlook Therapeutics Prices $5M Registered Direct Offering
28 May 2026 //
GLOBENEWSWIRE
Outlook Tx Wins ONS-5010 Appeal Following Formal Dispute Process
26 May 2026 //
GLOBENEWSWIRE
Outlook Therapeutics Reports Fiscal Q2 2026 Financial Results
15 May 2026 //
GLOBENEWSWIRE
CytomX Reports Q1 2026 Results and Business Update
07 May 2026 //
GLOBENEWSWIRE
CuraTeQ Gets Health Canada Nod for Bevacizumab Biosimilar
04 May 2026 //
INDPHARMAPOST
Aurobindo Pharma`s Curateq Receives Health Canada Approval
01 May 2026 //
ECONOMICTIMES
Outlook Therapeutics Announces $5M Registered Direct Offering
22 Apr 2026 //
GLOBENEWSWIRE
CytoDyn Presents Leronlimab Colorectal Data at AACR 2026
22 Apr 2026 //
GLOBENEWSWIRE
Outlook Completes FDR Meeting with FDA for ONS-5010/LYTENAVA
21 Apr 2026 //
GLOBENEWSWIRE
Adagene Showcases Muzastotug`s Role at AACR 2026
17 Apr 2026 //
FIRSTWORD PHARMA
Scientists Develop Way to Predict Bowel Cancer Response
14 Apr 2026 //
PHARMIWEB
Genmab: Rina-S/Bevacizumab Safe in Advanced Ovarian Cancer
13 Apr 2026 //
PHARMIWEB
Outlook Therapeutics Initiates FDA Dispute Resolution
07 Apr 2026 //
GLOBENEWSWIRE
EC Approve KEYTRUDA + Paclitaxel ± Bevacizumab for Ovarian Cancer
02 Apr 2026 //
PHARMIWEB
Onco360 Named National Pharmacy Partner For LIFYORLI
26 Mar 2026 //
GLOBENEWSWIRE
Outlook Therapeutics Finalizes $5.0M Public Offering
25 Mar 2026 //
GLOBENEWSWIRE
Outlook Therapeutics Prices $5M Public Offering
24 Mar 2026 //
GLOBENEWSWIRE
Outlook Therapeutics Announces Proposed Public Offering
23 Mar 2026 //
GLOBENEWSWIRE
Outlook Therapeutics Unveils $18.4M Non-Convertible Note
16 Mar 2026 //
GLOBENEWSWIRE
Varsetatug Masetecan Shows Promise in Late-Line Colorectal Cancer
16 Mar 2026 //
GLOBENEWSWIRE
Outlook Updates On FDA Meeting Regarding ONS-5010/LYTENAVA
05 Mar 2026 //
GLOBENEWSWIRE
CytoDyn Employs Creatv Bio`s LifeTracDx in Phase 2 Study
03 Mar 2026 //
PR NEWSWIRE
Keytruda Combo Improves OS in Platinum-Resistant Ovarian Cancer
27 Feb 2026 //
BUSINESSWIRE
Outlook Therapeutics Reports Q1 FY2026 Results and Corporate
17 Feb 2026 //
GLOBENEWSWIRE
Outlook Therapeutics Seeks FDA Type A Meeting Post-CRL Letter
11 Feb 2026 //
GLOBENEWSWIRE
Oncolytics Gets FDA Fast Track for Pelareorep in KRAS mCRC Cancer
04 Feb 2026 //
GLOBENEWSWIRE
FDA Grants Breakthrough Designation to Lilly`s Sofetabart
20 Jan 2026 //
PR NEWSWIRE
Cytomx Therapeutics Unveils 2026 Business Update And Milestones
08 Jan 2026 //
GLOBENEWSWIRE
Outlook Therapeutics Updates FDA Review Of ONS-5010 For Wet AMD
31 Dec 2025 //
GLOBENEWSWIRE
Outlook Therapeutics Announces New Employment Inducement Grants
26 Dec 2025 //
GLOBENEWSWIRE
Outlook Therapeutics Unveils Fiscal Year 2025 Financial Results
19 Dec 2025 //
GLOBENEWSWIRE
DESTINY-Ovarian01—ENHERTU Phase 3 Begins for HER2+Ovarian Cancer
09 Dec 2025 //
BUSINESSWIRE
Enterome`s EO2401 Demonstrates Survival Benefit in Phase 2 GBM
02 Dec 2025 //
GLOBENEWSWIRE
Outlook Therapeutics To Present At Piper Sandler Healthcare Conf
24 Nov 2025 //
GLOBENEWSWIRE
Outlook Therapeutics Accepts FDA`s ONS-5010 BLA For Wet AMD
13 Nov 2025 //
GLOBENEWSWIRE
Outlook Therapeutics Resubmits BLA For ONS-5010
03 Nov 2025 //
GLOBENEWSWIRE
Biodlink Ships Bevacizumab Internationally To Colombia
27 Oct 2025 //
PR NEWSWIRE
Leap Therapeutics Unveils Defiance Study Final Results at ESMO
20 Oct 2025 //
PR NEWSWIRE
AZ Faces FDA Challenge As Imfinzi-Lynparza Miss Survival Goal
19 Oct 2025 //
FIERCE PHARMA
KEYTRUDA® Combo Reduces Progression Risk In Platinum-Resistant
18 Oct 2025 //
BUSINESSWIRE
Summit Expands Ivonescimab Phase III To Include Harmoni-Gi3 Study
17 Oct 2025 //
BUSINESSWIRE
Merck`s KEYNOTE-B96 Phase 3 Trial Meets Secondary Endpoint
16 Oct 2025 //
BUSINESSWIRE
In Ovarian Cancer, Keytruda Follows PFS Win With Survival Showing
16 Oct 2025 //
FIERCE PHARMA
Outlook Therapeutics Provides Update On Type A Meeting With FDA
29 Sep 2025 //
GLOBENEWSWIRE
Leap Therapeutics To Present Defiance Study Part B Data At ESMO
25 Sep 2025 //
PR NEWSWIRE
FDA Grants BTD To R-DXd For Platinum-Resistant Ovarian Cancers
16 Sep 2025 //
INDPHARMAPOST
FDA Grants Breakthrough Tag to Raludotatug Deruxtecan in CDH6
15 Sep 2025 //
BUSINESSWIRE
Akeso Starts Global Cadonilimab Trial in Resistant Liver Cancer
15 Sep 2025 //
PR NEWSWIRE
Outlook Therapeutics to Showcase at 2025 EURETINA Innovation
03 Sep 2025 //
GLOBENEWSWIRE
Outlook Therapeutics Requests Type A Meeting with FDA
02 Sep 2025 //
GLOBENEWSWIRE
Outlook Provides FDA Review Update on ONS-5010 for Wet AMD
28 Aug 2025 //
GLOBENEWSWIRE
BioDlink’s Bevacizumab Gains 4th Emerging Market Nod in Indonesia
21 Aug 2025 //
PR NEWSWIRE
BioDlink Launches Bevacizumab in Colombia, Pakistan
13 Aug 2025 //
PR NEWSWIRE
Outlook Therapeutics Announces SMC Recommendation of Lytenava
10 Jun 2025 //
GLOBENEWSWIRE
BioDlink Achieves Argentina GMP for Global Compliance Push
05 Jun 2025 //
PR NEWSWIRE
Outlook Launches Lytenava in Germany and UK for Wet AMD
02 Jun 2025 //
GLOBENEWSWIRE
